Jonathan D Adachi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1984524/publications.pdf

Version: 2024-02-01

309 papers 18,996 citations

18887 64 h-index 128 g-index

318 all docs

318 docs citations

times ranked

318

14640 citing authors

#	Article	IF	CITATIONS
1	Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. Osteoporosis International, 2022, 33, 113-122.	1.3	11
2	Exploring the Association between Pain and Fracture Characteristics in Women with Osteoporotic Vertebral Fractures. Physiotherapy Canada Physiotherapie Canada, 2022, 74, 165-172.	0.3	1
3	Birth Weight and the Risk of Cardiovascular Outcomes: A Report From the Large Population-Based UK Biobank Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 827491.	1.1	6
4	Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007–2018. Rheumatology, 2022, 62, 158-168.	0.9	1
5	Relationship between Serum 25-Hydroxyvitamin D Level and Risk of Recurrent Stroke. Nutrients, 2022, 14, 1908.	1.7	7
6	Vertebral Fractures: Which Radiological Criteria Are Better Associated With the Clinical Course of Osteoporosis?. Canadian Association of Radiologists Journal, 2021, 72, 150-158.	1.1	9
7	Exploring changes in bone mass in individuals with a chronic spinal cord injury. Osteoporosis International, 2021, 32, 759-767.	1.3	6
8	Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. BMC Musculoskeletal Disorders, 2021, 22, 105.	0.8	37
9	Therapies for Preventing Bone Loss with Glucocorticoid Treatment. Current Osteoporosis Reports, 2021, 19, 34-39.	1.5	3
10	Identifying Patients with Osteoarthritis at Risk of Sarcopenia using the SARC-F. Canadian Geriatrics Journal, 2021, 24, 1-7.	0.7	7
11	Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskeletal Disorders, 2021, 22, 224.	0.8	23
12	Exploring Fear of Falling and Exercise Self-Efficacy in Older Women With Vertebral Fractures. Journal of Aging and Physical Activity, 2021, 29, 219-224.	0.5	5
13	Factors That Predict 1-Year Incident Hip and Non-Hip Fractures for Home Care Recipients: A Linked-Data Retrospective Cohort Study. Journal of the American Medical Directors Association, 2021, 22, 1035-1042.	1.2	3
14	Validation of the Fracture Risk Scale Home Care (FRS-HC) Across 4 Canadian Provinces. Journal of the American Medical Directors Association, 2021, 22, 1114-1116.	1.2	1
15	Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 177-190.	0.8	24
16	Management of social isolation and loneliness in community-dwelling older adults: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 2021, 11, e042828.	0.8	2
17	Cognitive decline is associated with an accelerated rate of bone loss and increased fracture risk in women: a prospective study from the Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research, 2021, 36, 2106-2115.	3.1	14
18	Preventing Fractures in Long-Term Care: Translating Recommendations to Clinical Practice. Journal of the American Medical Directors Association, 2021, 22, 36-42.	1.2	9

#	Article	IF	CITATIONS
19	A Valid and Precise Semiautomated Method for Quantifying Intermuscular Fat Intramuscular Fat in Lower Leg Magnetic Resonance Images. Journal of Clinical Densitometry, 2020, 23, 611-622.	0.5	3
20	Bone Marrow and Muscle Fat Infiltration Are Correlated among Postmenopausal Women With Osteoporosis: The AMBERS Cohort Study. Journal of Bone and Mineral Research, 2020, 35, 516-527.	3.1	14
21	A Higher Proportion of Home Care Recipients Experience Nonhip Fractures Than Long-Term Care Residents. Journal of the American Medical Directors Association, 2020, 21, 289-290.	1.2	3
22	The Effects of Home Exercise in Older Women With Vertebral Fractures: A Pilot Randomized Controlled Trial. Physical Therapy, 2020, 100, 662-676.	1.1	18
23	Promoting Osteoporosis Best Practices: A New Electronic Medical Record Tool. Journal of the American Medical Directors Association, 2020, 21, 1349-1352.	1.2	2
24	Romosozumab in the treatment of osteoporosis. Immunotherapy, 2020, 12, 965-981.	1.0	14
25	Relationship Between Obesity and Risk of Major Osteoporotic Fracture in Postmenopausal Women: Taking Frailty Into Consideration. Journal of Bone and Mineral Research, 2020, 35, 2355-2362.	3.1	13
26	A Risk Assessment Tool for Predicting Fragility Fractures and Mortality in the Elderly. Journal of Bone and Mineral Research, 2020, 35, 1923-1934.	3.1	10
27	An empirical comparison of methods for analyzing over-dispersed zero-inflated count data from stratified cluster randomized trials. Contemporary Clinical Trials Communications, 2020, 17, 100539.	0.5	3
28	Change in Quantitative Ultrasound-assessed Speed of Sound as a Function of Age in Women and Men and Association With the Use of Antiresorptive Agents: The Canadian Multicentre Osteoporosis Study. Journal of Clinical Densitometry, 2020, 23, 549-560.	0.5	1
29	Combining Frailty and Trabecular Bone Score Did Not Improve Predictive Accuracy in Risk of Major Osteoporotic Fractures. Journal of Bone and Mineral Research, 2020, 35, 1058-1064.	3.1	4
30	Evaluation of the Fracture Liaison Service within the Canadian Healthcare Setting. Journal of Osteoporosis, 2020, 2020, 1-6.	0.1	2
31	Association between frailty and risk of fall among diabetic patients. Endocrine Connections, 2020, 9, 1057-1064.	0.8	13
32	Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect. Journal of Bone and Mineral Research, 2020, 37, 1075-1076.	3.1	0
33	Determining known-group validity and test-retest reliability in the PEQ (personalized exercise) Tj ETQq $1\ 1\ 0.7843$	14 rgBT /C	Overlock 10
34	Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis. Journal of Bone and Mineral Research, 2019, 34, 2001-2011.	3.1	26
35	Management of Frailty: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Journal of the American Medical Directors Association, 2019, 20, 1190-1198.	1,2	102
36	Frailty and Risk of Fractures in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 507-513.	4.3	75

#	Article	IF	CITATIONS
37	Glucocorticoid induced osteoporosis. Expert Review of Endocrinology and Metabolism, 2019, 14, 259-266.	1.2	19
38	The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study. JBMR Plus, 2019, 3, e10211.	1.3	28
39	Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: Data from the Ontario Best Practices Research Initiative. Bone, 2019, 127, 129-134.	1.4	21
40	Incident Fragility Fractures Have a Long-Term Negative Impact on Health-Related Quality of Life of Older People: The Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research, 2019, 34, 838-848.	3.1	25
41	Denosumab Versus Risedronate in Glucocorticoidâ€Induced Osteoporosis: Final Results of a Twentyâ€Four–Month Randomized, Doubleâ€Blind, Doubleâ€Dummy Trial. Arthritis and Rheumatology, 2019, 71, 1174-1184.	2.9	102
42	Study protocol: design and rationale for an exploratory phase II randomized controlled trial to determine optimal vitamin D3 supplementation strategies for acute fracture healing. Pilot and Feasibility Studies, 2019, 5, 135.	0.5	5
43	One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. Journal of Bone and Mineral Research, 2019, 34, 419-428.	3.1	126
44	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 34-43.	5.5	244
45	Score Distributions of the Balance Outcome Measure for Elder Rehabilitation (BOOMER) in Community-Dwelling Older Adults With Vertebral Fracture. Journal of Geriatric Physical Therapy, 2019, 42, E87-E93.	0.6	2
46	Inter-rater reliability of DartfishTM movement analysis software for measuring maximum flexion and extension at the hip and knee in older adults with osteoporosis and osteopenia. Physiotherapy Theory and Practice, 2019, 35, 577-585.	0.6	2
47	Patient preferences for nutritional supplementation to improve fracture healing: a discrete choice experiment. BMJ Open, 2018, 8, e019685.	0.8	6
48	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes and Endocrinology,the, 2018, 6, 445-454.	5.5	148
49	Attitudes Toward and Management of Fibromyalgia. Journal of Clinical Rheumatology, 2018, 24, 243-249.	0.5	13
50	Novel Imaging Modalities in Osteoporosis Diagnosis and Risk Stratification. Current Treatment Options in Rheumatology, 2018, 4, 133-141.	0.6	2
51	Measuring Marrow Density and Area Using Peripheral Quantitative Computed Tomography at the Tibia: Precision in Young and Older Adults and Individuals With Spinal Cord Injury. Journal of Clinical Densitometry, 2018, 21, 269-280.	0.5	6
52	Investigating the Effects of Motion Streaks on pQCT-Derived Leg Muscle Density and Its Association With Fractures. Journal of Clinical Densitometry, 2018, 21, 130-139.	0.5	2
53	Evaluating Completeness of Reporting in Behavioral Interventions Pilot Trials. Research on Social Work Practice, 2018, 28, 577-584.	1.1	1
54	A Systematic Survey of Control Groups in Behavioral and Social Science Trials. Research on Social Work Practice, 2018, 28, 538-545.	1.1	5

#	Article	IF	CITATIONS
55	Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross-Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos). Journal of Bone and Mineral Research, 2018, 33, 569-579.	3.1	82
56	Does Muscle Atrophy and Fatty Infiltration Plateau or Persist in Chronic Spinal Cord Injury?. Journal of Clinical Densitometry, 2018, 21, 329-337.	0.5	12
57	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. Journal of Bone and Mineral Research, 2018, 33, 419-429.	3.1	45
58	Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting. Journal of Rheumatology, 2018, 45, 170-176.	1.0	24
59	Enhancing research publications and advancing scientific writing in health research collaborations: sharing lessons learnt from the trenches. Journal of Multidisciplinary Healthcare, 2018, Volume 11, 245-254.	1.1	6
60	Validation of a one year fracture prediction tool for absolute hip fracture risk in long term care residents. BMC Geriatrics, 2018, 18, 320.	1.1	10
61	Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? & amp;ndash; A systematic review of reviews: an update. Journal of Multidisciplinary Healthcare, 2018, Volume 11, 495-510.	1.1	69
62	Efficacy of a biomechanically-based yoga exercise program in knee osteoarthritis: A randomized controlled trial. PLoS ONE, 2018, 13, e0195653.	1.1	36
63	Getting fit for hip and knee replacement: a protocol for the Fit-Joints pilot randomized controlled trial of a multi-modal intervention in frail patients with osteoarthritis. Pilot and Feasibility Studies, 2018, 4, 127.	0.5	9
64	Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicentre osteoporosis study. BMC Geriatrics, 2018, 18, 4.	1.1	27
65	Vertebral Fractures and Morphometric Deformities. Journal of Bone and Mineral Research, 2018, 33, 1544-1545.	3.1	12
66	Relationships between fatty infiltration in the thigh and calf in women with knee osteoarthritis. Aging Clinical and Experimental Research, 2017, 29, 291-299.	1.4	21
67	Modifying the Phenotypic Frailty Model in Predicting Risk of Major Osteoporotic Fracture in the Elderly. Journal of the American Medical Directors Association, 2017, 18, 414-419.	1.2	6
68	An overview of osteoporosis and frailty in the elderly. BMC Musculoskeletal Disorders, 2017, 18, 46.	0.8	133
69	Population-Wide Impact of Non-Hip Non-Vertebral Fractures on Mortality. Journal of Bone and Mineral Research, 2017, 32, 1802-1810.	3.1	51
70	State of reporting of primary biomedical research: a scoping review protocol. BMJ Open, 2017, 7, e014749.	0.8	6
71	Baseline knee adduction moment interacts with body mass index to predict loss of medial tibial cartilage volume over 2.5 years in knee Osteoarthritis. Journal of Orthopaedic Research, 2017, 35, 2476-2483.	1.2	37
72	Spine bone mineral density increases after 6Âmonths of exclusive lactation, even in women who keep breastfeeding. Archives of Osteoporosis, 2017, 12, 73.	1.0	11

#	Article	IF	Citations
73	Development and validation of the Fracture Risk Scale (FRS) that predicts fracture over a 1-year time period in institutionalised frail older people living in Canada: an electronic record-linked longitudinal cohort study. BMJ Open, 2017, 7, e016477.	0.8	21
74	Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskeletal Disorders, 2017, 18, 174.	0.8	10
75	Facilitators and barriers to exercise adherence in patients with osteopenia and osteoporosis: a systematic review. Osteoporosis International, 2017, 28, 735-745.	1.3	58
76	Lean muscle volume of the thigh has a stronger relationship with muscle power than muscle strength in women with knee osteoarthritis. Clinical Biomechanics, 2017, 41, 92-97.	0.5	18
77	A Missed Opportunity in Bone Health: Vitamin D and Calcium Use in Elderly Femoral Neck Fracture Patients Following Arthroplasty. Geriatric Orthopaedic Surgery and Rehabilitation, 2017, 8, 215-224.	0.6	4
78	Corrigendum to "Risk Factors for Fracture in Diabetes: The Canadian Multicentre Osteoporosis Study― International Scholarly Research Notices, 2017, 2017, 1-1.	0.9	0
79	Development and validation of a new tool to measure the facilitators, barriers and preferences to exercise in people with osteoporosis. BMC Musculoskeletal Disorders, 2017, 18, 540.	0.8	204
80	Management of frailty: a protocol of a network meta-analysis of randomized controlled trials. Systematic Reviews, 2017, 6, 130.	2.5	15
81	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 56-60.	0.4	2
82	The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review. Journal of Osteoporosis, 2016, 2016, 1-5.	0.1	2
83	Frailty Change and Major Osteoporotic Fracture in the Elderly: Data from the Global Longitudinal Study of Osteoporosis in Women 3-Year Hamilton Cohort. Journal of Bone and Mineral Research, 2016, 31, 718-724.	3.1	31
84	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	3.1	29
85	Fracture Incidence in Adult Kidney Transplant Recipients. Transplantation, 2016, 100, 167-175.	0.5	42
86	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2016, 375, 1532-1543.	13.9	1,099
87	Quantifying fat and lean muscle in the lower legs of women with knee osteoarthritis using two different MRI systems. Rheumatology International, 2016, 36, 855-862.	1.5	8
88	A Comparison of CAROC and FRAX in Patients with Fragility Fracture. Journal of Rheumatology, 2016, 43, 1456-1457.	1.0	2
89	Trabecular Bone Score and Incident Fragility Fracture Risk in Adults with Reduced Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2032-2040.	2.2	58
90	Loss of health related quality of life following low-trauma fractures in the elderly. BMC Geriatrics, 2016, 16, 84.	1.1	51

#	Article	IF	Citations
91	Frequency of Bone Mineral Density Testing in Adult Kidney Transplant Recipients from Ontario, Canada: A Population-Based Cohort Study. Canadian Journal of Kidney Health and Disease, 2016, 3, 92.	0.6	4
92	Intermittent and constant pain and physical function or performance in men and women with knee osteoarthritis: data from the osteoarthritis initiative. Clinical Rheumatology, 2016, 35, 371-379.	1.0	26
93	The reliability of a segmentation methodology for assessing intramuscular adipose tissue and other soft-tissue compartments of lower leg MRI images. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 237-244.	1.1	13
94	Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism. Nutrition Research, 2016, 36, 328-336.	1.3	20
95	Risk factors for fracture in adult kidney transplant recipients. World Journal of Transplantation, 2016, 6, 370.	0.6	21
96	Do Knee Moments Normalized to Measures of Knee Cartilage Area Better Classify the Severity of Knee Osteoarthritis?. Journal of Applied Biomechanics, 2015, 31, 415-422.	0.3	1
97	The Tissue-Selective Estrogen Complex: A Review of Current Evidence. Rheumatology and Therapy, 2015, 2, 47-58.	1.1	8
98	Comparison between Frailty Index of Deficit Accumulation and Phenotypic Model to Predict Risk of Falls: Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) Hamilton Cohort. PLoS ONE, 2015, 10, e0120144.	1.1	41
99	The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes. Journal of Aging Research, 2015, 2015, 1-9.	0.4	8
100	Characterizing the Assessment and Management of Vitamin D Levels in Patients with Osteoporosis in Clinical Practice: A Chart Review Initiative. Journal of Osteoporosis, 2015, 2015, 1-7.	0.1	0
101	Osteoporosis Prescribing in Long-Term Care: Impact of a Provincial Knowledge Translation Strategy. Canadian Journal on Aging, 2015, 34, 137-148.	0.6	8
102	Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures. Bone, 2015, 77, 107-114.	1.4	18
103	Bone lead (Pb) content at the tibia is associated with thinner distal tibia cortices and lower volumetric bone density in postmenopausal women. Bone, 2015, 79, 58-64.	1.4	32
104	Development of a Skeletal Muscle Mimic Phantom Compatible with QCT and MR Imaging. Journal of Medical Imaging and Radiation Sciences, 2015, 46, 174-181.	0.2	4
105	Improving Reliability of pQCT-Derived Muscle Area and Density Measures Using a Watershed Algorithm for Muscle and Fat Segmentation. Journal of Clinical Densitometry, 2015, 18, 93-101.	0.5	35
106	A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part I: Short-term Precision and Validity. Journal of Clinical Densitometry, 2015, 18, 124-135.	0.5	16
107	A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part II: 1-Yr Change, Long-Term Precision, and Least Significant Change. Journal of Clinical Densitometry, 2015, 18, 260-269.	0.5	6
108	Knee adduction moment relates to medial femoral and tibial cartilage morphology in clinical knee osteoarthritis. Journal of Biomechanics, 2015, 48, 3495-3501.	0.9	34

#	Article	lF	CITATIONS
109	Ten-year incident osteoporosis-related fractures in the population-based Canadian Multicentre Osteoporosis Study â€" Comparing site and age-specific risks in women and men. Bone, 2015, 71, 237-243.	1.4	58
110	Successful knowledge translation intervention in long-term care: final results from the vitamin D and osteoporosis study (ViDOS) pilot cluster randomized controlled trial. Trials, 2015, 16, 214.	0.7	41
111	Comparison of Fracture Risk Prediction among Individuals with Reduced and Normal Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 646-653.	2.2	133
112	Fat Infiltration in the Leg is Associated with Bone Geometry and Physical Function in Healthy Older Women. Calcified Tissue International, 2015, 97, 353-363.	1.5	19
113	Recommendations for preventing fracture in long-term care. Cmaj, 2015, 187, 1135-1144.	0.9	46
114	Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Current Medical Research and Opinion, 2015, 31, 1391-1401.	0.9	16
115	Assessing the Reliability of a Semiautomated Segmentation Algorithm for Quantifying Erosions in the Metacarpophalangeal Joints of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 1582-1586.	1.0	1
116	A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part III: SD, SEE, LSC Association With Fragility Fractures. Journal of Clinical Densitometry, 2015, 18, 408-418.	0.5	4
117	Bilateral atypical femoral fractures: how much symmetry is there on imaging?. Skeletal Radiology, 2015, 44, 1579-1584.	1.2	21
118	Muscle Density and Bone Quality of the Distal Lower Extremity Among Individuals with Chronic Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation, 2015, 21, 282-293.	0.8	15
119	Differences inIn VitroDisintegration Time among Canadian Brand and Generic Bisphosphonates. Journal of Osteoporosis, 2014, 2014, 1-6.	0.1	1
120	Systemic Lupus Erythematosus, Osteoporosis, and Fractures. Journal of Rheumatology, 2014, 41, 1913-1915.	1.0	10
121	The three-year incidence of fracture in chronic kidney disease. Kidney International, 2014, 86, 810-818.	2.6	189
122	Knee Power Is an Important Parameter in Understanding Medial Knee Joint Load in Knee Osteoarthritis. Arthritis Care and Research, 2014, 66, 687-694.	1.5	15
123	Implementing a Knowledge Translation Intervention in Long-Term Care: Feasibility Results From the Vitamin D and Osteoporosis Study (ViDOS). Journal of the American Medical Directors Association, 2014, 15, 943-945.	1.2	12
124	Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW). Journal of Bone and Mineral Research, 2014, 29, 260-267.	3.1	47
125	Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period. Annals of Pharmacotherapy, 2014, 48, 954-961.	0.9	24
126	Heterogeneity in Skeletal Load Adaptation Points to a Role for Modeling in the Pathogenesis of Osteoporotic Fracture. Journal of Clinical Densitometry, 2014, 17, 170-176.	0.5	5

#	Article	IF	CITATIONS
127	Appropriate Osteoporosis Treatment by Family Physicians inÂResponse to FRAX vs CAROC Reporting: Results FromÂa Randomized Controlled Trial. Journal of Clinical Densitometry, 2014, 17, 458-465.	0.5	7
128	Normative Data for Multisite Quantitative Ultrasound: The Canadian Multicenter Osteoporosis Study. Journal of Clinical Densitometry, 2014, 17, 534-540.	0.5	6
129	Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW). Journal of Bone and Mineral Research, 2014, 29, 487-493.	3.1	192
130	Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos). Archives of Osteoporosis, 2014, 9, 169.	1.0	24
131	Efficacy of Vitamin D Supplementation in Depression in Adults: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 757-767.	1.8	116
132	Empirically Based Composite Fracture Prediction Model From the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 817-826.	1.8	14
133	Effect of Odanacatib on BMD and Fractures: Estimates from Bayesian Univariate and Bivariate Meta-analyses. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3070-3079.	1.8	6
134	Build Better Bones With Exercise: Protocol for a Feasibility Study of a Multicenter Randomized Controlled Trial of 12 Months of Home Exercise in Women With a Vertebral Fracture. Physical Therapy, 2014, 94, 1337-1352.	1.1	21
135	A Frailty Index predicts 10-year fracture risk in adults age 25Âyears and older: results from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporosis International, 2014, 25, 2825-2832.	1.3	71
136	Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW). Calcified Tissue International, 2014, 94, 223-231.	1.5	36
137	Prospectively measured 10-year changes in health-related quality of life and comparison with cross-sectional estimates in a population-based cohort of adult women and men. Quality of Life Research, 2014, 23, 2707-2721.	1.5	10
138	Frailty index of deficit accumulation and falls: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) Hamilton cohort. BMC Musculoskeletal Disorders, 2014, 15, 185.	0.8	44
139	Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture. Journal of Bone and Mineral Research, 2014, 29, 2545-2551.	3.1	7
140	Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Canadian Family Physician, 2014, 60, 324-33.	0.1	97
141	High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group. Current Osteoporosis Reports, 2013, 11, 136-146.	1.5	182
142	How to define responders in osteoarthritis. Current Medical Research and Opinion, 2013, 29, 719-729.	0.9	75
143	Multisite quantitative ultrasound for the prediction of fractures over 5 years of follow-up: The Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research, 2013, 28, 2027-2034.	3.1	35
144	Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporosis International, 2013, 24, 59-67.	1.3	38

#	Article	IF	Citations
145	Evidence for impaired skeletal load adaptation among Canadian women with type 2 diabetes mellitus: Insight into the BMD and bone fragility paradox. Metabolism: Clinical and Experimental, 2013, 62, 1401-1405.	1.5	23
146	Bone mineralization is elevated and less heterogeneous in adults with type 2 diabetes and osteoarthritis compared to controls with osteoarthritis alone. Bone, 2013, 54, 76-82.	1.4	32
147	Frailty and Fracture, Disability, and Falls: A Multiple Country Study From the Global Longitudinal Study of Osteoporosis in Women. Journal of the American Geriatrics Society, 2013, 61, 327-334.	1.3	113
148	Calcium and Vitamin D Intake and Mortality: Results from the Canadian Multicentre Osteoporosis Study (CaMos). Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3010-3018.	1.8	49
149	Accumulation of bone strontium measured by in vivo XRF in rats supplemented with strontium citrate and strontium ranelate. Bone, 2013, 52, 63-69.	1.4	27
150	A critical review of brand and generic alendronate for the treatment of osteoporosis. SpringerPlus, 2013, 2, 550.	1.2	12
151	An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Annals of the Rheumatic Diseases, 2013, 72, 911-917.	0.5	76
152	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis. Menopause, 2013, 20, 130-137.	0.8	35
153	Adapting the Iconic Pain Assessment Tool Version 2 (IPAT2) for Adults and Adolescents With Arthritis Pain Through Usability Testing and Refinement of Pain Quality Icons. Clinical Journal of Pain, 2013, 29, 253-264.	0.8	16
154	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	1.1	63
155	Patterns of Anti-Osteoporosis Medication Use among Women at High Risk of Fracture: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e82840.	1.1	6
156	Risk Factors for Fracture in Diabetes: The Canadian Multicentre Osteoporosis Study. ISRN Epidemiology, 2013, 2013, 1-6.	0.6	2
157	The Relationship between Radial Bone Properties and Disease Activity and Physical Function in Individuals with Rheumatoid Arthritis. Physiotherapy Canada Physiotherapie Canada, 2012, 64, 284-291.	0.3	3
158	Effect of Low-Intensity Pulsed Ultrasound on the Cartilage Repair in People With Mild to Moderate Knee Osteoarthritis: A Double-Blinded, Randomized, Placebo-Controlled Pilot Study. Archives of Physical Medicine and Rehabilitation, 2012, 93, 35-42.	0.5	88
159	Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2012, 50, 1288-1293.	1.4	129
160	An interdisciplinary knowledge translation intervention in long-term care: Study protocol for the vitamin D and osteoporosis study (ViDOS) pilot cluster randomized controlled trial. Implementation Science, 2012, 7, 48.	2.5	22
161	Characteristics associated with anti-osteoporosis medication use: Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone, 2012, 51, 975-980.	1.4	36
162	Leisure-Time Physical Activity and Perceived Health in People Living with Osteoporosis. Applied Research in Quality of Life, 2012, 7, 391.	1.4	5

#	Article	IF	CITATIONS
163	Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. Journal of Bone and Mineral Research, 2012, 27, 645-653.	3.1	143
164	Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. Journal of Bone and Mineral Research, 2012, 27, 1381-1389.	3.1	66
165	The burden of illness of osteoporosis in Canadian men. Journal of Bone and Mineral Research, 2012, 27, 1830-1838.	3.1	30
166	Fracture Risk in Living Kidney Donors: A Matched Cohort Study. American Journal of Kidney Diseases, 2012, 59, 770-776.	2.1	40
167	Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. Journal of Bone and Mineral Research, 2012, 27, 202-210.	3.1	47
168	Clinical Risk Factors for Fracture in Diabetes: A Matched Cohort Analysis. Journal of Clinical Densitometry, 2011, 14, 416-421.	0.5	20
169	Reproducibility of Peripheral Quantitative Computed Tomography Measurements at the Radius and Tibia in Healthy Pre- and Postmenopausal Women. Canadian Association of Radiologists Journal, 2011, 62, 183-189.	1.1	16
170	Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. Journal of Clinical Densitometry, 2011, 14, 212-219.	0.5	85
171	Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. Journal of Clinical Densitometry, 2011, 14, 226-236.	0.5	45
172	FRAX® Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & Densitometry & Densitometry & Densitometry & Densitometry, 2011, 14, 223-225.	0.5	19
173	Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. American Journal of Medicine, 2011, 124, 1043-1050.	0.6	446
174	Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. Bone, 2011, 48, 1298-1304.	1.4	16
175	Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2011, 49, 493-498.	1.4	78
176	Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 2011, 7, 157.	0.9	32
177	If you don't take it & amp; ndash; it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Therapeutics and Clinical Risk Management, 2011, 7, 181.	0.9	9
178	Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture. Journal of the American Geriatrics Society, 2011, 59, 2084-2090.	1.3	55
179	Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporosis International, 2011, 22, 817-827.	1.3	144
180	Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial. Osteoporosis International, 2011, 22, 2539-2549.	1.3	29

#	Article	IF	CITATIONS
181	Clinical Risk Factors for Recurrent Fracture after Hip Fracture: A Prospective Study. Calcified Tissue International, 2011, 88, 425-431.	1.5	9
182	Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial. Calcified Tissue International, 2011, 89, 427-433.	1.5	12
183	Multiplanar reconstruction recovers morphological cartilage assessment reproducibility from maloriented coronal MRI scans. Magnetic Resonance in Medicine, 2011, 65, 790-795.	1.9	O
184	Predicting fractures in an international cohort using risk factor algorithms without BMD. Journal of Bone and Mineral Research, 2011, 26, 2770-2777.	3.1	58
185	The burden of osteoporotic fractures beyond acute care: the Canadian Multicentre Osteoporosis Study (CaMos). Age and Ageing, 2011, 40, 602-607.	0.7	25
186	Atypical Femoral Fractures in Patients Taking Longterm Alendronate. Journal of Rheumatology, 2011, 38, 2686-2687.	1.0	1
187	Role of teriparatide in treatment of glucocorticoid-induced osteoporosis. Therapeutics and Clinical Risk Management, 2010, Volume 6, 497-503.	0.9	13
188	The Safe Functional Motion test is reliable for assessment of functional movements in individuals at risk for osteoporotic fracture. Clinical Rheumatology, 2010, 29, 143-150.	1.0	10
189	Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study. Journal of Bone and Mineral Research, 2010, 25, 2239-2250.	3.1	155
190	What are the beliefs, attitudes and practices of front-line staff in long-term care (LTC) facilities related to osteoporosis awareness, management and fracture prevention?. BMC Geriatrics, 2010, 10, 73.	1.1	15
191	Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Current Medical Research and Opinion, 2010, 26, 599-604.	0.9	9
192	Combined Vertebral Fracture Assessment and Bone Mineral Density Measurement: A Patient-friendly New Tool with an Important Impact on the Canadian Risk Fracture Classification. Canadian Association of Radiologists Journal, 2010, 61, 194-200.	1.1	24
193	Normative Bone Mineral Density Z-Scores for Canadians Aged 16 to 24 Years: The Canadian Multicenter Osteoporosis Study. Journal of Clinical Densitometry, 2010, 13, 267-276.	0.5	14
194	Impact of Prevalent Fractures on Quality of Life: Baseline Results From the Global Longitudinal Study of Osteoporosis in Women. Mayo Clinic Proceedings, 2010, 85, 806-813.	1.4	159
195	A Scoping Review of Strategies for the Prevention of Hip Fracture in Elderly Nursing Home Residents. PLoS ONE, 2010, 5, e9515.	1.1	32
196	Hip fracture prevention strategies in long-term care: a survey of Canadian physicians' opinions. Canadian Family Physician, 2010, 56, e392-7.	0.1	10
197	Health-related Quality of Life in Canadian Adolescents and Young Adults: Normative Data Using the SF-36. Canadian Journal of Public Health, 2009, 100, 449-452.	1.1	33
198	Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Therapeutic Advances in Musculoskeletal Disease, 2009, 1, 5-11.	1.2	11

#	Article	IF	Citations
199	Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy. Journal of Rheumatology, 2009, 36, 1835-1837.	1.0	74
200	Family Physicians' Personal and Practice Characteristics that Are Associated with Improved Utilization of Bone Mineral Density Testing and Osteoporosis Medication Prescribing. Population Health Management, 2009, 12, 131-138.	0.8	5
201	Glucocorticoid-induced osteoporosis: treatment update and review. Therapeutic Advances in Musculoskeletal Disease, 2009, 1, 71-85.	1.2	48
202	Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: A 12-week, randomized, double-blind, placebo-controlled, exploratory study. Clinical Therapeutics, 2009, 31, 1747-1753.	1.1	26
203	Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?. Osteoporosis International, 2009, 20, 1785-1793.	1.3	8
204	Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporosis International, 2009, 20, 1101-1106.	1.3	22
205	Bone turnover markers in the management of postmenopausal osteoporosis. Clinical Biochemistry, 2009, 42, 929-942.	0.8	171
206	Vertebral Fracture Status and the World Health Organization Risk Factors for Predicting Osteoporotic Fracture Risk. Journal of Bone and Mineral Research, 2009, 24, 495-502.	3.1	67
207	Bridging the Osteoporosis Quality Chasm. Journal of Bone and Mineral Research, 2009, 24, 3-7.	3.1	30
208	Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture. Journal of Bone and Mineral Research, 2009, 24, 1308-1313.	3.1	111
209	Repeat Low-Trauma Fractures Occur Frequently Among Men and Women Who Have Osteopenic BMD. Journal of Bone and Mineral Research, 2009, 24, 1515-1522.	3.1	75
210	Injury Measurement Properties of Serum Interleukin-6 Following Lumbar Decompression Surgery. Journal of Surgical Research, 2009, 157, 161-167.	0.8	8
211	Body Weight–Supported Treadmill Training for Patients With Hip Fracture: A Feasibility Study. Archives of Physical Medicine and Rehabilitation, 2009, 90, 2125-2130.	0.5	9
212	Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Cmaj, 2009, 181, 265-271.	0.9	327
213	Raloxifene use in clinical practice. Menopause, 2009, 16, 413-421.	0.8	36
214	Prevalence of Osteoporosis in Osteoarthritic Patients Undergoing Total Hip or Total Knee Arthroplasty. Archives of Physical Medicine and Rehabilitation, 2008, 89, 2373-2374.	0.5	35
215	Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone, 2008, 43, 672-678.	1.4	25
216	Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clinical and Experimental Research, 2008, 20, 585-592.	1.4	29

#	Article	IF	Citations
217	Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 5465-5476.	0.8	164
218	Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective. Nature Clinical Practice Rheumatology, 2008, 4, 240-248.	3.2	29
219	Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3785-3793.	1.8	205
220	Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial). Chest, 2008, 134, 794-800.	0.4	39
221	Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Canadian Family Physician, 2008, 54, 394-402.	0.1	41
222	Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study. Clinical Therapeutics, 2007, 29, 2055-2067.	1.1	37
223	Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. Journal of Clinical Epidemiology, 2007, 60, 336-344.	2.4	51
224	Patient Adherence to Osteoporosis Medications. Drugs and Aging, 2007, 24, 37-55.	1.3	125
225	Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New England Journal of Medicine, 2007, 357, 1799-1809.	13.9	1,734
226	Therapeutic advances in the treatment of osteoporosis. Expert Opinion on Therapeutic Patents, 2007, 17, 277-285.	2.4	3
227	The Use of Hip Protectors in Long-Term Care Facilities: A Survey of Nursing Home Staff. Journal of the American Medical Directors Association, 2007, 8, 229-232.	1.2	14
228	The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review. BMC Musculoskeletal Disorders, 2007, 8, 97.	0.8	38
229	Bisphosphonates for the Treatment of Postmenopausal Osteoporosis: An Update. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 145-152.	1.3	0
230	Calcium and vitamin D for osteoporotic fracture prevention. Polish Archives of Internal Medicine, 2007, 117, 441-442.	0.3	1
231	Canadian Quality Circle pilot project in osteoporosis: rationale, methods, and feasibility. Canadian Family Physician, 2007, 53, 1694-700.	0.1	6
232	Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clinical Interventions in Aging, 2007, 2, 275-82.	1.3	5
233	Extremity magnetic resonance imaging. Journal of Rheumatology, 2007, 34, 1634-5; author reply 1635.	1.0	0
234	Prevalence of knee abnormalities in patients with osteoarthritis and anterior cruciate ligament injury identified with peripheral magnetic resonance imaging: a pilot study. Canadian Association of Radiologists Journal, 2007, 58, 167-75.	1.1	13

#	Article	IF	Citations
235	Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Current Medical Research and Opinion, 2006, 22, 1425-1436.	0.9	40
236	Treating osteoporosis: economic aspects of bisphosphonate therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 1457-1467.	0.9	3
237	What is the Number of Older Canadians Needed to Screen by Measurement of Bone Density to Detect an Undiagnosed Case of Osteoporosis? A Population-Based Study From CaMos. Journal of Clinical Densitometry, 2006, 9, 413-418.	0.5	6
238	Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease. Drug Safety, 2006, 29, 1133-1152.	1.4	43
239	Changes to Osteoporosis Prevalence According to Method of Risk Assessment. Journal of Bone and Mineral Research, 2006, 22, 228-234.	3.1	40
240	The Natural Progression of Health-Related Quality of Life: Results of a Five-Year Prospective Study of SF-36 Scores in a Normative Population. Quality of Life Research, 2006, 15, 527-536.	1.5	63
241	Determinants of health-related quality of life in women with vertebral fractures. Osteoporosis International, 2006, 17, 355-363.	1.3	34
242	Glucocorticoid-Induced Osteoporosis. Women's Health, 2006, 2, 65-74.	0.7	7
243	Parathyroid hormone for the treatment of osteoporosis: a systematic review. Cmaj, 2006, 175, 52-59.	0.9	67
244	In whom and how to prevent glucocorticoid-induced osteoporosis. Best Practice and Research in Clinical Rheumatology, 2005, 19, 1039-1064.	1.4	9
245	Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporosis International, 2005, 16, 568-578.	1.3	69
246	Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. Osteoporosis International, 2005, 16, 208-215.	1.3	17
247	Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporosis International, 2005, 16, 1461-1474.	1.3	98
248	A Systematic Review of the Effect of Alendronate on Bone Mineral Density in Men. Journal of Clinical Densitometry, 2005, 8, 7-13.	0.5	9
249	Similar Proportions of Women Lose Bone Mineral Density With Raloxifene or Alendronate Treatment. Journal of Clinical Densitometry, 2005, 8, 273-277.	0.5	6
250	Measurement of cervical flexor endurance following whiplash. Disability and Rehabilitation, 2005, 27, 801-807.	0.9	51
251	Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clinical and Experimental Research, 2005, 17, 150-156.	1.4	27
252	Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis. Drug Safety, 2005, 28, 721-730.	1.4	65

#	Article	IF	Citations
253	Case report: osteogenesis imperfecta Elusive cause of fractures. Canadian Family Physician, 2005, 51, 1655-7.	0.1	3
254	Stability of Normative Data for the SF-36. Canadian Journal of Public Health, 2004, 95, 387-391.	1.1	19
255	The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Current Medical Research and Opinion, 2004, 20, 903-910.	0.9	35
256	Efficacy of risedronate on clinical vertebral fractures within six months. Current Medical Research and Opinion, 2004, 20, 433-439.	0.9	171
257	Prediction of falls using a risk assessment tool in the acute care setting. BMC Medicine, 2004, 2, 1.	2.3	115
258	Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the Hip Fracture Projections Wrong?. Journal of Bone and Mineral Research, 2004, 20, 898-905.	3.1	181
259	Rational use of oral bisphosphonates for the treatment of osteoporosis. Current Osteoporosis Reports, 2004, 2, 17-23.	1.5	15
260	Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate. Journal of Clinical Densitometry, 2004, 7, 255-261.	0.5	211
261	The Impact of Fragility Fracture on Health-Related Quality of Life. Drugs and Aging, 2004, 21, 711-730.	1.3	14
262	The treatment of glucocorticoid-induced osteoporosis. Journal of Steroid Biochemistry and Molecular Biology, 2004, 88, 337-349.	1.2	28
263	Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment. Clinical Therapeutics, 2004, 26, 15-28.	1.1	142
264	Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?. Journal of Rheumatology, 2004, 31, 1993-5.	1.0	11
265	Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis International, 2003, 14, 808-813.	1.3	86
266	The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporosis International, 2003, 14, 895-904.	1.3	125
267	A 6-Mo Home-Based Exercise Program May Slow Vertebral Height Loss. Journal of Clinical Densitometry, 2003, 6, 391-400.	0.5	10
268	What Predicts Early Fracture or Bone Loss on Bisphosphonate Therapy?. Journal of Clinical Densitometry, 2003, 6, 315-322.	0.5	17
269	In Vivo Measurement of Apparent Trabecular Bone Structure of the Radius in Women With Low Bone Density Discriminates Patients with Recent Wrist Fracture from Those Without Fracture. Journal of Clinical Densitometry, 2003, 6, 35-43.	0.5	20
270	Poster 28. Archives of Physical Medicine and Rehabilitation, 2003, 84, E10-E11.	0.5	1

#	Article	IF	CITATIONS
271	Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition. Canadian Journal of Physiology and Pharmacology, 2003, 81, 952-958.	0.7	11
272	IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis. Endocrine Reviews, 2002, 23, 524-528.	8.9	149
273	II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women. Endocrine Reviews, 2002, 23, 508-516.	8.9	396
274	Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3609-3617.	1.8	490
275	III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis. Endocrine Reviews, 2002, 23, 517-523.	8.9	260
276	Early Effects of Raloxifene on Clinical Vertebral Fractures at 12 Months in Postmenopausal Women With Osteoporosis. Archives of Internal Medicine, 2002, 162, 1140.	4.3	143
277	Cockcroft-Gault equation and estimation of creatinine clearance: The Reply. American Journal of Medicine, 2002, 112, 684-685.	0.6	2
278	Diagnosis and management of vertebral fractures in elderly adults. American Journal of Medicine, 2002, 113, 220-228.	0.6	204
279	Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis. Drug Safety, 2002, 25, 781-790.	1.4	17
280	Corticosteroid-Induced Osteoporosis. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2002, 1, 271-279.	1.8	8
281	North American Male Reference Population for Speed of Sound in Bone at Multiple Skeletal Sites. Journal of Clinical Densitometry, 2002, 5, 63-71.	0.5	14
282	Is There Regional Variation in the SF-36 Scores of Canadian Adults?. Canadian Journal of Public Health, 2002, 93, 233-237.	1.1	14
283	The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskeletal Disorders, 2002, 3, 11.	0.8	119
284	Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Education and Counseling, 2002, 47, 245-255.	1.0	86
285	Corticosteroid-Induced Osteoporosis. Drug Safety, 2001, 24, 607-624.	1.4	23
286	Estimation of creatinine clearance in elderly persons in long-term care facilities. American Journal of Medicine, 2001, 111, 569-573.	0.6	36
287	Positive Effect of Etidronate Therapy Is Maintained After Drug Is Terminated in Patients Using Corticosteroids. Journal of Clinical Densitometry, 2001, 4, 363-371.	0.5	7
288	TREATMENT OF ESTABLISHED BONE LOSS AFTER RENAL TRANSPLANTATION WITH ETIDRONATE1. Transplantation, 2001, 71, 669-673.	0.5	42

#	Article	IF	CITATIONS
289	Systemic Lupus Erythematosus Presenting as Subacute Delirium in an 82â€Yearâ€Old Woman. Journal of the American Geriatrics Society, 2001, 49, 458-461.	1.3	8
290	Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis and Rheumatism, 2001, 44, 202-211.	6.7	485
291	Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Practice and Research in Clinical Rheumatology, 2001, 15, 469-481.	1.4	13
292	Glucocorticoid-induced osteoporosis. Drug Development Research, 2000, 49, 120-134.	1.4	4
293	Management of corticosteroid-induced osteoporosis. Seminars in Arthritis and Rheumatism, 2000, 29, 228-251.	1.6	111
294	Glucocorticoid-induced osteoporosis. Current Rheumatology Reports, 2000, 2, 53-61.	2.1	7
295	In Vivo Detection of Structural Differences Between Dominant and Nondominant Radii Using Peripheral Quantitative Computed Tomography. Journal of Clinical Densitometry, 1999, 2, 413-422.	0.5	32
296	Gender Differences in Normal Age-Dependent Patterns of Radial Bone Structure and Density. Journal of Clinical Densitometry, 1999, 2, 163-173.	0.5	15
297	Metabolic Bone Disease in Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1999, 5, 200-211.	0.9	35
298	Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. New England Journal of Medicine, 1998, 339, 292-299.	13.9	1,192
299	Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis. New England Journal of Medicine, 1997, 337, 382-388.	13.9	694
300	A Model for Osteoporosis Education of Students and Health Professionals. Drug Information Journal, 1997, 31, 287-291.	0.5	0
301	A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 1997, 104, 64-70.	1.1	22
302	Corticosteroid-Induced Osteoporosis. American Journal of the Medical Sciences, 1997, 313, 41-49.	0.4	61
303	Gymnastic training and bone density in pre-adolescent females. Medicine and Science in Sports and Exercise, 1997, 29, 443-450.	0.2	117
304	Slow-release sodium fluoride with calcium prevented new spinal fractures. ACP Journal Club, 1996, 124, 34.	0.1	0
305	Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis and Rheumatism, 1993, 36, 750-756.	6.7	297
306	Corticosteroid-induced osteoporosis. Seminars in Arthritis and Rheumatism, 1993, 22, 375-384.	1.6	99

#	Article	IF	CITATIONS
307	N of 1 randomized trials for investigating new drugs. Contemporary Clinical Trials, 1990, 11, 88-100.	2.0	127
308	An N of 1 Service: Applying the Scientific Method in Clinical Practice. Scandinavian Journal of Gastroenterology, 1988, 23, 22-29.	0.6	46
309	Gold induced thrombocytopenia: 12 cases and a review of the literature. Seminars in Arthritis and Rheumatism, 1987, 16, 287-293.	1.6	46